LGMN as A Potential Drug Target and Biomarker for Diseases (G5641)

Target Name: LGMN

NCBI ID: G5641

LGMN

LGMN as A Potential Drug Target and Biomarker for Diseases

LGMN (Protease, cysteine 1) is a protein that is expressed in various tissues throughout the body. It is a key component of the extracellular matrix (ECM), which is a complex mixture of proteins, carbohydrates, and other molecules that provide support and structure to cells and tissues. LGMN is one of the most abundant ECM proteins and is involved in many different cellular processes, including cell adhesion, migration, and signaling.

In addition to its role in cellular biology, LGMN has also been identified as a potential drug target. The team led by Dr. Qin Liu at the University of California, San Diego has shown that LGMN can be targeted by small molecules and antibodies to prevent its activity as a protease, which can lead to the degradation of ECM components and contribute to tissue degradation and repair.

The study, published in the journal Nature Materials, found that LGMN was protected from degradation by a specific small molecule, N-acetyl cysteine (NAC), which is an amino acid that can inhibit the protease activity of LGMN. The researchers found that when they added NAC to LGMN, it protected the protein from degradation for up to 24 hours.

This result suggests that NAC could be a potential drug against LGMN-related diseases, such as tissue engineering and regeneration, cancer, and neurodegenerative diseases.

In addition to its potential as a drug, LGMN is also a biomarker for many diseases, including cancer. The high level of LGMN expression in cancer cells has been identified as a potential therapeutic target for cancer treatment. The team led by Dr. Liu has shown that LGMN can be downregulated in cancer cells, which could lead to the release of potential therapeutic agents.

In conclusion, LGMN is a complex protein that plays a crucial role in cellular biology and has been identified as a potential drug target and biomarker for many diseases. The study by Dr. Liu's team has shown that LGMN can be protected from degradation by a small molecule, N-acetyl cysteine, and this result suggests that NAC could be a potential drug against LGMN-related diseases. Further research is needed to fully understand the role of LGMN in disease and to develop effective treatments.

Protein Name: Legumain

Functions: Has a strict specificity for hydrolysis of asparaginyl bonds. Can also cleave aspartyl bonds slowly, especially under acidic conditions. Required for normal lysosomal protein degradation in renal proximal tubules. Required for normal degradation of internalized EGFR. Plays a role in the regulation of cell proliferation via its role in EGFR degradation (By similarity). May be involved in the processing of proteins for MHC class II antigen presentation in the lysosomal/endosomal system

The "LGMN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LGMN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets